- Home
- ARQQ vs TLSI Comparison
ARQQ vs TLSI Comparison
Compare ARQQ & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQQ
- TLSI
- Stock Information
- Founded
- ARQQ 2017
- TLSI 2010
- Country
- ARQQ United Kingdom
- TLSI United States
- Employees
- ARQQ N/A
- TLSI N/A
- Industry
- ARQQ Computer Software: Prepackaged Software
- TLSI Medical Specialities
- Sector
- ARQQ Technology
- TLSI Health Care
- Exchange
- ARQQ Nasdaq
- TLSI Nasdaq
- Market Cap
- ARQQ 173.1M
- TLSI 160.4M
- IPO Year
- ARQQ N/A
- TLSI N/A
- Fundamental
- Price
- ARQQ $14.20
- TLSI $5.52
- Analyst Decision
- ARQQ Strong Buy
- TLSI Strong Buy
- Analyst Count
- ARQQ 1
- TLSI 6
- Target Price
- ARQQ $52.00
- TLSI $11.75
- AVG Volume (30 Days)
- ARQQ 547.5K
- TLSI 67.6K
- Earning Date
- ARQQ 05-19-2025
- TLSI 03-27-2025
- Dividend Yield
- ARQQ N/A
- TLSI N/A
- EPS Growth
- ARQQ N/A
- TLSI N/A
- EPS
- ARQQ N/A
- TLSI N/A
- Revenue
- ARQQ $293,000.00
- TLSI $29,431,000.00
- Revenue This Year
- ARQQ $1,818.77
- TLSI $55.43
- Revenue Next Year
- ARQQ N/A
- TLSI $50.09
- P/E Ratio
- ARQQ N/A
- TLSI N/A
- Revenue Growth
- ARQQ N/A
- TLSI 58.99
- 52 Week Low
- ARQQ $3.72
- TLSI $3.50
- 52 Week High
- ARQQ $52.79
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- ARQQ 43.67
- TLSI 52.49
- Support Level
- ARQQ $16.50
- TLSI $5.23
- Resistance Level
- ARQQ $20.70
- TLSI $5.72
- Average True Range (ATR)
- ARQQ 2.52
- TLSI 0.35
- MACD
- ARQQ 0.01
- TLSI 0.02
- Stochastic Oscillator
- ARQQ 19.19
- TLSI 78.72
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product QuantumCloud. The firm operates in one segment that is, the provision of cybersecurity services via satellite and terrestrial platforms. The company operates and generates its revenue from UK.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.